Consolidated balance sheet
|
in CHF 1 000 |
|
Notes |
|
30.09.2022 |
|
31.12.2021 |
|
Current assets |
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
|
3 025 |
|
2 835 |
|
Securities |
|
4 |
|
3 025 046 |
|
3 641 112 |
|
Other assets |
|
|
|
108 |
|
135 |
|
|
|
|
|
3 028 179 |
|
3 644 082 |
|
Total assets |
|
|
|
3 028 179 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
Short-term borrowings from banks |
|
5 |
|
303 000 |
|
355 000 |
|
Other short-term liabilities |
|
|
|
3 785 |
|
5 431 |
|
Tax liabilities |
|
|
|
95 |
|
158 |
|
|
|
|
|
306 880 |
|
360 589 |
|
Total liabilities |
|
|
|
306 880 |
|
360 589 |
|
|
|
|
|
|
|
|
|
Shareholders' equity |
|
|
|
|
|
|
|
Share capital |
|
6 |
|
11 080 |
|
11 080 |
|
Treasury shares |
|
6 |
|
(36 508) |
|
(9 205) |
|
Retained earnings |
|
|
|
2 746 727 |
|
3 281 618 |
|
|
|
|
|
2 721 299 |
|
3 283 493 |
|
Total liabilities and shareholders' equity |
|
|
|
3 028 179 |
|
3 644 082 |
|
|
|
|
|
|
|
|
|
Net asset value per share in CHF |
|
|
|
49.60 |
|
59.40 |
The notes are an integral part of the condensed consolidated interim financial statements.
The condensed consolidated interim financial statements were approved by the Board of Directors of BB Biotech AG on October 18, 2022.